Here are six things to know:
1. At 60 months of follow-up, the Mobi-C device demonstrated superiority in overall trial success compared to the control anterior cervical discectomy and fusion treatment, which is the traditional option for treating cervical degenerative disc disease.
2. Mobi-C implanted at two contiguous levels showed an overall success rate of 62.8 percent, while the rate of success using ACDF was 34.1 percent.
3. The rate of subsequent surgery at the index level was lower for Mobi-C at 3.8 percent compared to 16.2 percent for ACDF.
4. The mean return to work time was 45.9 days for Mobi-C compared to 66.8 days for ACDF.
5. Mobi-C showed an 82 percent improvement in neck disability index based on success criteria compared to 56.6 percent for ACDF.
6. According to LDR President and CEO Christophe Lavigne, the FDA’s approval of Mobi-C’s labeling updated with five-year safety and efficacy data is another important milestone for LDR.
More articles on devices:
Providence Medical adds surface technology to DTRAX Line: 4 takeaways
Spine Wave launches StaXx XD Xpandable Device: 5 key notes
K2M to introduce Lamellar Titanium Technology: 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
